Forxiga maximum dosage?

What is the maximum dosage of Forxiga?

Forxiga, also known as dapagliflozin, is a medication used to treat type 2 diabetes and certain cases of heart failure. According to the FDA label [1], the recommended dosage of Forxiga is 10 mg once daily. However, the maximum dosage has not been established in clinical trials.

Why is the maximum dosage of Forxiga not established?

The clinical trials for Forxiga did not evaluate the safety and efficacy of higher dosages beyond 10 mg per day. Therefore, taking more than the recommended 10 mg per day is not recommended.

Can patients with kidney disease take higher dosages of Forxiga?

For patients with severe renal impairment, the recommended dosage of Forxiga is 5 mg once daily. Patients with mild or moderate renal impairment should follow the same dosing instructions as those with normal renal function, which is 10 mg once daily.

Interactions and contraindications

Taking higher dosages of Forxiga may increase the risk of certain interactions or contraindications. Patients should inform their healthcare providers about all medications they are taking, including prescription and non-prescription medications, vitamins, and herbal supplements.

Regulatory approval and patent information

Forxiga was first approved by the FDA in 2014 under a New Chemical Entity (NCE) exclusivity [2]. The patent for Forxiga is owned by AstraZeneca and is due to expire in [2][3] 2031.

Clinical trial results and side effects

Clinical trials have shown that dapagliflozin, the active ingredient in Forxiga, reduced the risk of major adverse cardiovascular events, kidney disease progression, and hospitalizations for heart failure in patients with type 2 diabetes and heart failure [4].

Biosimilars and generic entry

Biosimilars or generic versions of Forxiga may become available after the patent expires. However, the availability and pricing of these alternatives will depend on various regulatory and market factors.

Sources:

[1] FDA. (2022). Forxiga label. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/202714s012lbl.pdf

[2] FDA. (2014). Forxiga approval package. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/nda/2014/201415Orig1s000TOC.cfm

[3] DrugPatentWatch.com. (n.d.). Forxiga patent expiry. Retrieved from https://www.drugpatentwatch.com/patent/214-2006/patent-expiry

[4] FDA. (2020). Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and multi-vessel coronary artery disease. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2024620